Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 8Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Cardiotoxicity 3Triple Negative Breast Neoplasms 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Heart Failure 2Glioblastoma 2Endometrial Neoplasms 2Endometrial Hyperplasia 2Waldenstrom Macroglobulinemia 1Rectal Neoplasms 1Precancerous Conditions 1Polycystic Ovary Syndrome 1Overall Survival 1Neoplastic Cells, Circulating 1Nasopharyngeal Carcinoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1

Interventions

Cisplatin 39Radiotherapy 21Carboplatin 21Cetuximab 20Paclitaxel 19Docetaxel 17Radiotherapy, Intensity-Modulated 15pembrolizumab 14Fluorouracil 13Drug Therapy 10Nivolumab 8Radiation 6cemiplimab 5atezolizumab 5Panitumumab 5Oxaliplatin 5Erlotinib Hydrochloride 5Chemoradiotherapy 5Afatinib 5Surgical Procedures, Operative 4durvalumab 3Surveys and Questionnaires 3Methotrexate 3Leucovorin 3Lapatinib 3130-nm albumin-bound paclitaxel 3toripalimab 2palbociclib 2osimertinib 2dacomitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Squamous Cell × Atorvastatin × Clear all
NCT04915183 2026-06-03

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡